Ultomiris (ravulizumab) is an antibody pharmaceutical. Ravulizumab was first approved as Ultomiris on 2018-12-21. It is used to treat atypical hemolytic uremic syndrome in the USA. It has been approved in Europe to treat paroxysmal hemoglobinuria. It is known to target complement C5.
|Indication||atypical hemolytic uremic syndrome, paroxysmal hemoglobinuria|
|Drug Class||Monoclonal antibodies: humanized, immunomodulating|